Merck (MRK) Receivables (2009 - 2026)
Merck (MRK) posted quarterly Receivables of $12.2 billion for Q1 2026, up 13.16% year-over-year from $10.8 billion in Q1 2025, and up 3.69% quarter-over-quarter from $11.8 billion in Q4 2025.
Merck (MRK) Receivables (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Receivables for 18 consecutive years, with $12.2 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables rose 13.16% year-over-year to $12.2 billion; the TTM figure through Mar 2026 stood at $12.2 billion (up 13.16% YoY), while the FY2025 annual figure was $11.8 billion, up 14.57% from the prior year.
- Receivables advanced to $12.2 billion in Q1 2026 per MRK's latest filing, from $11.8 billion in the prior quarter.
- Across five years, Receivables topped out at $12.2 billion in Q1 2026 and bottomed at $10.0 billion in Q4 2022.
- Historically, Receivables has averaged $11.0 billion across 5 years, with a median of $10.9 billion in 2023.
- Annual changes were most pronounced in 2022 — Receivables surged 755.76% — and 2025, when it decreased 5.07%.
- Merck's Receivables stood at $10.0 billion in 2022, then advanced by 3.9% to $10.3 billion in 2023, then fell by 0.69% to $10.3 billion in 2024, then advanced by 14.57% to $11.8 billion in 2025, then grew by 3.69% to $12.2 billion in 2026.
- Business Quant data shows MRK's Receivables at $12.2 billion in Q1 2026, $11.8 billion in Q4 2025, and $12.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 14.33 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 10.23 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 5.90 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 12.49 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 10.34 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 10.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.56 Bn |
| Mar 31, 2026 | 12.21 Bn |
| Dec 31, 2025 | 11.78 Bn |
| Sep 30, 2025 | 12.12 Bn |
| Jun 30, 2025 | 11.85 Bn |
| Mar 31, 2025 | 10.79 Bn |
| Dec 31, 2024 | 10.28 Bn |
| Sep 30, 2024 | 11.38 Bn |
| Jun 30, 2024 | 11.64 Bn |
| Mar 31, 2024 | 11.37 Bn |
| Dec 31, 2023 | 10.35 Bn |
| Sep 30, 2023 | 10.39 Bn |
| Jun 30, 2023 | 11.03 Bn |
| Mar 31, 2023 | 10.89 Bn |
| Dec 31, 2022 | 9.96 Bn |
| Sep 30, 2022 | 10.05 Bn |
| Jun 30, 2022 | 10.29 Bn |
| Mar 31, 2022 | 10.55 Bn |
| Dec 31, 2021 | 1.16 Bn |
| Sep 30, 2021 | 9.97 Bn |